Company Description
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program.
The company’s lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.
It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals.
In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder.
It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries.
The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited.
DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
| Country | United States |
| Founded | 1998 |
| IPO Date | Sep 28, 2000 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 58 |
| CEO | James Brown |
Contact Details
Address: 10240 Bubb Road Cupertino, California 95014-4166 United States | |
| Phone | 408 777 1417 |
| Website | durect.com |
Stock Details
| Ticker Symbol | DRRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001082038 |
| CUSIP Number | 266605104 |
| ISIN Number | US2666055007 |
| Employer ID | 94-3297098 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. James E. Brown D.V.M. | Co-Founder, Chief Executive Officer, President and Director |
| Timothy M. Papp M.B.A. | Chief Financial Officer and Secretary |
| Dr. Norman L. Sussman M.D. | Chief Medical Officer |
| Judy R. Joice | Senior Vice President of Operations and Corporate Quality Assurance |
| Dr. WeiQi Lin M.D., Ph.D. | Executive Vice President of Research and Development and Principal Scientist |
| Jian Li M.B.A. | Senior Vice President of Finance, Corporate Controller and Secretary |
| Dr. Su Il Yum Ph.D. | Executive Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 19, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |
| Sep 26, 2024 | 8-K | Current Report |
| Sep 25, 2024 | 8-K/A | [Amend] Current report |
| Sep 25, 2024 | 8-K | Current Report |
| Aug 23, 2024 | EFFECT | Notice of Effectiveness |
| Aug 19, 2024 | UPLOAD | Filing |
| Aug 14, 2024 | S-3 | Registration statement under Securities Act of 1933 |